GVR Report cover Recombinant DNA Technology Market Size, Share & Trends Report

Recombinant DNA Technology Market Size, Share & Trends Analysis Report By Product (Therapeutic Agent, Vaccine, Biotech Crops, Specialty Chemicals), By Component, By Application, By End-use, And Segment Forecasts, 2018 - 2025

  • Report ID: GVR-1-68038-872-5
  • Number of Pages: 210
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Report Overview

The global recombinant DNA technology market size to be valued at USD 844.6 billion by 2025. Recombinant DNA (rDNA) technology has offered scientists with unprecedented control over the genetic material. This has extended its usage in widespread applications including conventional as well as non-conventional applications. Over the past years, this space has witnessed tremendous achievement in the production of recombinant drugs and therapeutics without the help of human donors. 

Recombinant DNA Technology Market size, by medical product

The classical example of this achievement is the commercial success of genetically engineered insulin for diabetes treatment. The biotech and pharmaceutical firms are engaged in deciphering the potential of rDNA techniques in various aspects of disease management. This is mainly to combat the soaring burden of chronic diseases and keep pace with the growing therapeutics demand.

Furthermore, the gradual evolution of rDNA techniques has drafted new vistas in taking biopharmaceutical development a step ahead by enabling the construction of a recombinant DNA molecule. The presence of a robust biopharmaceuticals pipeline, in particular, the recombinant proteins pipeline; is expected to drive the adoption of this technology. Development of recombinant products using rDNA techniques accompanied by CRISPR/Cas9 nuclease, ZFN, and TALEN for easy & precise genome editing with no limitation by organisms is largely responsible for the growth of this space. Dozens of review studies carried out by researchers are evident for the efficiency of rDNA technology. 

Growth in Genetically Modified (GM) crop hectarage around the world is a testament to the success of this technology in the agriculture and food sector. This has triggered its usage in other non-conventional applications such as the development of biofuel and biopesticides to address environmental issues. However, the use of this technology has been a topic of controversies as a result of attendant ethical considerations in various applications such as gene therapy. In each of the diverse fields of medicine, agriculture, and the environment, scientific and ethical concerns vary in a discipline-specific manner.

Recombinant DNA Technology Market Trends

Remarkable developments in the industry to treat life threatening human diseases such as infectious diseases, diabetes, and cancer are some of the important factors affecting the expansion of the market. Advances in recombinant technologies have aided in the development of long-acting therapeutic proteins for drug development, the introduction of gene therapy, and novel molecular medicine. Positive impact on the treatment of genetic diseases and increasing advancements are expected to support the growth of the market during the forecast period.

Leading biopharmaceutical companies, and research institutes are collaborating strategically with key manufacturers to develop innovative treatments based on recombinant DNA technology. Such market partnerships are anticipated to boost the expansion of the global market during the forecast period.

The high cost and side effects associated with gene treatments such as Cytokine Release Syndrome (CRS) or Neurological Toxicities, are limiting the market growth.Additionally, scientific, regulatory, and ethical constraints involved with gene therapy are expected to limit market expansion during the forecast period.

Product Insights

rDNA technology has revolutionized the medical field and is having an ever-increasing impact on clinical medicine. It has facilitated disease treatment by insertion of new genes in place of damaged & diseased genes. The medical segment is further bifurcated into the therapeutic agents, recombinant protein, and vaccines. Out of all, therapeutic agents captured dominance over its counterpart segments owing to the presence of a substantial number of genetically engineered products for clinical applications.

However, vaccines are expected to be a source of lucrative revenue generation in the coming years due to the presence of a robust vaccine pipeline. Advancements in genetic engineering and process development are anticipated to drive growth in this segment. The non-medical segment of this market is majorly driven by the success of GM crops.

Global hectarage of biotech crops is observed to rise from 110-fold from 1.7 million hectares (1996) to 185.1 million hectares (2016). The top 5 countries that are engaged in planting biotech crops by hectarage are the USA, Brazil, Argentina, Canada, and India. Major GM crops are soybean, maize, cotton, and canola. The rise in the penetration of associated technologies such as genome editing in plant tissue engineering is expected to usher progress in this segment.

Component Insights

The expression system and cloning vector are recognized as the two key elements of this technology. Expression systems captured the largest share owing to the ongoing developments for efficient protein expression and for its further isolation on a large scale. Majorly used expression systems are mammalian, bacterial, insects, and yeast. The development of cell lines such as HEK293 and Chinese Hamster Ovarian (CHO) has contributed to the significant share of mammalian expression systems. 

In addition, ongoing research studies to explore the potential of plant as expression system are expected to drive the adoption of plan expression systems for GM product development in the coming years. Cloning vectors are recognized as the backbone for the production of DNA inserts. In 2016, Cohen was honored with the “2016 Biotechnology Heritage Award” for creating rDNA plasmids. Such achievements are expected to positively influence the growth of this segment throughout the forecast period.

Application Insights

Rapid advances in genetic engineering have played a major role in reshaping the usage of these techniques in health & disease, agriculture, and the environment. Health & disease application has accounted for the large share and is expected to maintain its dominance throughout the forecast period. This large share can be attributed to the presence of a wide range of recombinant products for human disease treatment such as drugs, vaccines, and enzymes replacements. Moreover, the extended use of this technology for animal disease treatment has also driven the progress of this segment. 

With the growing burden of crop improvement and consequent stress on farmers to meet the customer’s needs, this technology has gradually evolved as a panacea for addressing these issues of the agriculture sector. This, in turn, has resulted in a notable success of the recombination techniques in food and agriculture applications. Other applications, such as biofuel production, are expected to witness considerable growth in the coming years. This is mainly due to ongoing research activities to augment the scope of the space.

End-use Insights

Various end-use segments served by this recombinant DNA technology market include pharmaceutical & biotech entities, academic & research institutes, and other industrial entities. Pharmaceutical & biotech firms are major beneficiaries in this market as the techniques accelerate their drug development capabilities. Moreover, the end-products using rDNA techniques in this segment are highly valued and observed to have significant improvement in productivity. Hence, these organizations account for a larger share. 

Moreover, significant capital expenditure taken up by the companies for the development of a wide range of recombinant human therapeutics is supportive of the estimated share. These organizations are anticipated to maintain dominance in the coming years as a consequence of rising adoption for biologics production.

Regional Insights

The largest share of the North America region can be attributed to the fact that a substantial number of biopharmaceutical manufacturing participants are headquartered in the U.S. Moreover, the presence of effective regulatory bodies to monitor the various ethical and scientific concerns pertaining to the use of technology have driven regional growth. In July 2017, this country witnessed the 1st FDA approval for U.S. gene therapy treatment. The treatment was developed for leukemia, as a result of a collaboration between the University of Pennsylvania and Novartis Corp. This, in turn, is anticipated to nurture the implementation of rDNA techniques in the region. 

Recombinant DNA Technology Market share by region

The presence of low-cost manufacturing centers in the Asian economies, such as China, has driven significant attention from global entities to translocate their business in this region. Furthermore, Japan is recognized as one of the world’s largest per capita importers of food and feed developed using modern biotechnology tools. Japan’s regulatory system for GE crops continues to improve. Moreover, there is no significant trade barrier in Japan to hamper GE products export from western countries. As a result, Asia Pacific is expected to emerge as the fastest-growing regional market.

Recombinant DNA Technology Market Trends by Region

Key Companies & Market Share Insights

Some key participants operating in the space include F. Hoffmann-La Roche Ltd (Genentech, Inc); Profacgen; Amgen Inc; Novartis AG; GenScript; Pfizer Inc; Novo Nordisk A/S; Eli Lilly and Company; Sanofi; Merck & Co., Inc.; Biogen; Biocon; GlaxoSmithKline plc; New England Biolabs.; Cibus; Monsanto Company, and Horizon Discovery Group PLC. These participants are engaged in collaborative alliances to offer their services in the various life science domain. Moreover, entities are continuously expanding their manufacturing facilities as a viable strategy to stay competitive in the market space. 

Recent Developments

  • In December 2022, Amgen Inc. an American transnational biopharmaceutical company acquired Horizon rectifiers plc. The accession of horizon was an excellent occasion for amgen furnishing innovative drugs that addressed the requirements of cases who suffer from serious conditions.

  • In March 2022, VBI Vaccines Inc. released PreHevbrio a Recombinant Hepatitis B Vaccine in the United States for the forestallment of infection caused by all known subtypes of the hepatitis B contagion(HBV) in grown-ups.

Recombinant DNA Technology Market Report Scope

Report Attribute


Revenue forecast in 2025

USD 844.6 billion

Base year for estimation


Forecast period

2017 - 2025

Quantitative units

Revenue in USD million/billion and CAGR from 2017 to 2025

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, component, application, end-use, and region

Regional scope

North America; Europe; Asia Pacific; Latin America; Middle East & Africa

Country scope

U.S.; Canada; UK; Germany; Japan; China; Brazil; South Africa

Key companies profiled

F. Hoffmann-La Roche Ltd (Genentech, Inc); Profacgen; Amgen Inc; Novartis AG; GenScript; Pfizer Inc; Novo Nordisk A/S; Eli Lilly and Company; Sanofi; Merck & Co., Inc.; Biogen; Biocon; GlaxoSmithKline plc; New England Biolabs.; Cibus; Monsanto Company, Horizon Discovery Group PLC

Customization scope

Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options

Global Recombinant DNA Technology Market Segmentation

This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global recombinant DNA technology market on the basis of product, component, application, end-use, and region:

Global Recombinant DNA Technology Market Segmentation

  • Product Outlook (Revenue, USD Billion, 2014 - 2025)

    • Medical

      • Therapeutic Agent

      • Human Protein

      • Vaccine

    • Non-medical

      • Biotech Crops

      • Specialty Chemicals

      • Others

  • Component Outlook (Revenue, USD Billion, 2014 - 2025)

    • Expression System

      • Mammalian

      • Bacteria

      • Yeast

      • Baculovirus / insect

      • Others

    • Cloning Vector

  • Application Outlook (Revenue, USD Billion, 2014 - 2025)

    • Food & Agriculture

    • Health & Disease

      • Human

      • Animal

    • Environment

    • Others

  • End-use Outlook (Revenue, USD Billion, 2014 - 2025)

    • Biotechnology and Pharmaceutical Companies

    • Academic & Government Research Institutes

    • Others

  • Regional Outlook (Revenue, USD Billion, 2014 - 2025)

    • North America

      • The U.S.

      • Canada

    • Europe

      • Germany

      • The U.K.

    • Asia Pacific

      • China

      • Japan

    • Latin America

      • Brazil

    • Middle East & Africa

      • South Africa

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.